Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. 

On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc. (NASDAQ:EOLS) to $15 from $19 while maintaining an Outperform rating, reflecting updated expectations following a softer-than-anticipated preannounced fourth quarter. Despite the near-term adjustment, the continued Outperform stance signals confidence in Evolus’ longer-term growth trajectory and the durability of its competitive positioning within the medical aesthetics market.

Operationally, Evolus, Inc. (NASDAQ:EOLS) continues to demonstrate solid underlying momentum. During its third-quarter 2025 earnings call, the company reported revenue of $69 million, representing 13% year-over-year growth, driven by sustained global demand for Jeuveau and theU.S. launch of Evolysse. These two products anchor Evolus’ expanding portfolio and highlight the company’s ability to execute across both established and newly introduced offerings, supporting revenue diversification and market penetration.

Evolus operates as a performance beauty company focused on injectable aesthetic treatments in the cash-pay market. By building a portfolio of differentiated, physician-led brands and expanding its international footprint, the company is positioning itself for continued share gains over time. Headquartered in Newport Beach, California, and founded in 2012, Evolus, Inc. (NASDAQ:EOLS) appears well placed to translate its growing product portfolio and global demand trends into sustained top-line growth as short-term volatility normalizes.

While we acknowledge the potential of EOLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.